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SUMMARy
Candida albicans is the most common cause of fungal infections worldwide. Non-albicans 
Candida species play an important role in vulvovaginal candidiasis and invasive infections. Most 
cases of infections are endogenous. In case of patients with immune disorders this opportunistic 
pathogen causes both surface, systemic infections, and candidemia. Symptoms depend on the area 
affected. Candidiasis are treated with antimycotics; these include clotrimazole, nystatin, lucon-
azole, voriconazole, amphotericin B, and echinocandins. The emergence of drug resistance and the 
side effects of currently available antifungals are becoming a major problem in the management of 
Candida spp. infection.
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INTRODUCTION
Candidiasis is a fungal infection caused by yeasts that belong to the class Saccharomycetes. 
Candida albicans is the most common cause of fungal infections worldwide (24) There are over 20 
species of Candida spp. yeasts that can cause infection in humans, ive most common of them are C. 
albicans, C. glabrata, C. krusei, C. parapsilosis and C. tropicalis. In the majority of cases, there are 
infections with yeast of Candida genus that were previously present in the body (endogenous infec-
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tions), and the reason of disease process is the disturbance of the balance between yeast and host. 
Exogenous infections are rare. In case of patients with immune disorders, this opportunistic patho-
gen causes both surface (the oral cavity, oropharynx, oesophagus, and vagina), systemic infections 
and candidemia. Another reason for the development of infections caused by Candida spp. is the 
disruption of the balance in the microorganism of the human body (42). The most common causes of 
the occurrence of candidiasis are: immunosuppressant or steroids treatments, long-term catheteriza-
tion, invasive medical procedures, treatment with broad-spectrum antibiotic, destruction of skin by 
deep skin burns, local disorders of the gastrointestinal tract, diabetes mellitus, premature very low 
birth weight infants, immunologically compromised individuals, spread of hIV infection (31, 42). 
Pathogenesis of candidiasis depends on the virulence factors of the fungus allowing colonization 
and invasion of tissues, as well as avoiding host immune responses. C. albicans virulence factors 
include: complexity of cell wall structure, adhesion, pleomorphism, enzymatic activity, molecular 
mimicry, phenotypic variation. To the dificulty in treating patients with Candida spp. infections 
contribute also bioilms and secreted aspartyl proteinases. Bioilms are having inluence to higher 
resistance to both antifungal drugs and the host immune response. Secreted aspartyl proteinases 
(SAP) are a degradative enzymes which is associated with invasion (22).
Diagnosis of fungal infections is based on microscopic studies, microbiological cultures and 
identiication of cultured fungal species, serological tests (detection of antigens and antibodies) and 
molecular ones (14). Respiratory, gastrointestinal, and oesophageal candidiasis require an endos-
copy to diagnose (10).
Candidiasis symptoms depend on the area affected (16). Most candidal infections result in 
complications such as redness, itching, and discomfort, though untreated complications in certain 
populations may be severe or even fatal. In immunocompetent people, candidiasis is usually a lo-
calized infection of the skin, nails or mucosal membranes, including the oral cavity and pharynx, 
esophagus, and vagina (penis) (29); less commonly in healthy individuals, the gastrointestinal tract, 
urinary tract and respiratory tract are sites of candida infection (26). Candidiasis is treated with 
antimycotics; these include clotrimazole, nystatin, luconazole, voriconazole, amphotericin B, and 
echinocandins. Infectious Diseases Society of America in 2016 carried out a revision of the clini-
cal practice guideline for candidiasis depending on the site of infection and its severity (27). The 
supplementation of pharmacological treatment is lowcarbohydrate diet and probiotic preparations.
Oropharyngeal candidiasis
Infection of the mucous membranes of the mouth and throat (colloquially called a thrush) is 
quite a common disease in non-healthy people. however, it most often affects people with immune 
disorders. Additional factors that favour the occurrence of such an infection are: salivary gland 
dysfunction, blood group 0, carbohydrate-rich diet, neonatal period, pregnancy. Candida albicans 
is the most common species associated with thrush, seven other species within the Candida genus 
have been attributed to the disease in the oral cavity: C. glabrata, C. guillermondii, C. kruesi, C. lu-
sitaniae, C. parapsilosis, C. pseudotropicalis, C. stellatoidea, and C. tropicalis (38). An estimated 
30–60% of healthy adults carry Candida species within the oral cavity. The majority of these micro-
organisms exist as commensal colonization rather than as a pathologic process (25). The diagnosis 
of oral candidiasis is based on the clinical appearance alone. If empiric treatment is ineffective, the 
material should be taken from pathological changes for mycological examination. Basic diagnostics 
also includes cultures on an agar medium and biochemical identiication with a susceptibility mark. 
histologic examination, serological tests and detection of genetic material of the fungus using mo-
lecular biology techniques may be a supplement to the diagnosis which is important in the diagnosis 
of invasive and systemic fungi. In order to distinguish commensal carriage from infection, a salivary 
examination is performed, based on a quantitative analysis of the colony forming units (CFU) (21).
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Oral thrush is characterized by the presence of whitish, usually painless plague mainly in the 
mucous membrane of the cheeks and palate. Changes can also occur around the corners of the mouth 
(angular cheilitis), on the tongue (acute atrophic glossitis) and gums (stomatitis). Very often changes 
in the mouth coexist with the candidiasis in the throat and esophagus – there is discomfort during 
swallowing. Oral candidiasis is classiied by the duration of symptoms on acute candidiasis (pseu-
domembranous, atrophic) and chronic candidiasis (pseudomembranous, atrophic, hyperplasia) (30).
The treatment should primarily include minimizing the impact of risk factors, the use of topi-
cal antifungal agents (suspensions, solutions, gels) and oral hygiene. In case of patients with im-
munodeiciency who suffer from severe course of oral mycosis, general treatment should be used. 
Antifungal drug should be selected on the basis of the micogram. Treatment should be continued for 
at least 2 weeks after the symptoms have resolved.
Oesophagus candidiasis
Candida spp. are a component of the physiological lora of the digestive tract in 40–80% of 
the population. In some situations, usually associated with immune disorders, these fungi can cause 
opportunistic infections. According to h. Daniell research, the use of proton pump inhibitors is 
an additional risk factor for developing oesophagia (7). The clinical picture of candidiasis varies 
from benign asymptomatic mucous membrane infections to generalized multi-organ infections with 
mortality up to 50% (15). Symptoms of oesophagus mycosis include dysphagia, sodynophagia, pain 
and burning sensation in the epigastrium and behind the breastbone, as well as secondary weight 
loss. The test of choice is endoscopy of the upper gastrointestinal tract, histologic conirmation of 
candida in the esophagus is the gold standard for diagnosis (18). The current irst-line treatment is 
luconazole administered orally at a dose of 200–400 mg / day (3–6 mg / kg / day) for 14–21 days, 
which can then be administered long-term at a dose of 100–200 mg 3 × during the week to prevent 
the recurrence of the disease. In case of patients with dificult swallowing, intravenous luconazole 
400 mg / day (6 mg/ kg/ day) is recommended. Resistant and refractory infections can occur and 
may require alternative agents for treatment or long-term antifungal prophylaxis to reduce recur-
rence. For luconazole resistance, itraconazole 200 mg/ day or voriconazole 2 × 200 mg orally 
or intravenously for 14–21 days are used (13, 17) Amphotericin B deoxycholate 0.3 to 0.7 mg/kg 
daily can be used in patients with refractory candida esophagitis, but it has serious medication side 
effects and should be avoided if possible. Posaconazole 400 mg twice daily has been effective in 
refractory esophageal candidiasis as well (13, 27). Empirical antifungal therapy is recommended 
when there is a suspicion of oesophagus mycosis in case of patients with impaired immune system 
(e.g. during chemotherapy or with AIDS) (27). The lack of effective treatment of oesophagia can 
lead to complications such as bleeding or secondary esophageal stenosis and to the development of 
esophago-bronchial istula.
Gastrointestinal candidiasis
Candida spp., despite their natural occurrence in the digestive tract, are rarely the cause of 
mycosis of the stomach or intestines. Candida spp. are common in the stomach of healthy peo-
ple, without causing any lesions. In immunocompetent patients with ulcerations or erosions 
of the gastric mucosa, yeasts can colonize them, but they do not affect the healing process (8). 
however, results from animal models argue that Candida spp. colonization delays healing of 
inlammatory lesions and that inlammation promotes colonization (20). Candidiasis almost 
always has a secondary character to previous pathological changes occurring in the stomach and 
most frequently relates to patients with neoplastic diseases (8). Colonization of Candida albicans 
may enhance inlammation because it is associated with elevated levels of the pro-inlammatory 
DIAGNOSIS AND TREATMENT OF MUCOSA CAnDiDA SPP. INFECTIONS – A REVIEW ARTICLE
Pobrane z czasopisma Annales C - Biologia http://biologia.annales.umcs.pl
Data: 04/08/2020 22:29:40
UM
CS
64
cytokine IL-17 and IL-23 (20). In the course of gastro-intestinal candidiasis, ulcers are most often 
found, with supericial erosions, whitish plaques or purulent membranes. The lesions located in the 
small and large intestine have a similar appearance, and the frequency of their occurrence in these 
parts of the intestine is similar. Clinical symptoms are usually non-speciic. These include diarrhea, 
nausea, vomiting, latulence and abdominal pain, as well as gastrointestinal bleeding (8, 9). The 
treatment recommendations are the same as for esophageal candidiasis (27).
Vulvovaginal candida infection (VVC) 
Vulvovaginal candidiasis is, after bacterial vaginosis, the second most common abnormality 
associated with vaginal biocenosis (2). The infection usually occurs by self-infection as a result of 
disturbance of the normal bacterial lora or reduced immunity of the organism. It is estimated that 
75% of women will experience at least one episode of VVC over a lifetime, and approximately 
40–45% will be treated for this reason at least twice (2). In 5–10% of patients, the recurrent form of 
mycosis will develop. Asymptomatic colonization affects 10–15% of women (36). The most com-
mon pathogen is Candida albicans (70–89% of cases), less often C. glabrata (3.4–20%), C. crusei, 
C. tropicalis, C. kefyr, C. parapsilosis. (34, 41). Factors conducive to vulvovaginal candidiasis in-
clude conditions of reduced immunity of the body, an important factor conducive to infection are 
hormonal changes. Estrogens increase the adherence of yeasts to mucous membranes (contracep-
tion, hormone replacement therapy), while progesterone reduces cellular immunity, and thus pro-
motes infections in the second phase of the menstrual cycle and in the third trimester of pregnancy 
(28, 45). A diagnosis of Candida VVC can usually be made clinically. Signs include pruritus, irrita-
tion, vaginal soreness, external dysuria, and dyspareunia often accompanied by a change in vaginal 
discharge (white, thick, curd-like), vulvar edema, erythema, excoriation, issures. These symptoms 
and signs are nonspeciic and can be the result of a variety of infectious and noninfectious etiologies. 
Diagnosis should be conirmed by a wet mount preparation with the use of saline and 10% potas-
sium hydroxide to demonstrate the presence of yeast or hyphae, before proceeding with empirical 
antifungal therapy. Vulvovaginal candidiasis is associated with ph <4.5. For those with negative wet 
mount indings, vaginal cultures for Candida spp. should be obtained.
VVC can be classiied as either uncomplicated (as in ~90% of cases) or complicated (~10% 
of cases) (5). Complicated VVC is deined as severe or recurrent disease (more than 4 episodes of 
symptomatic VVC within 1 year (40).), infection due to Candida species other than C. albicans, and/
or VVC in an abnormal host (5). Recommended treatment of uncomplicated VVC is 150 mg dose of 
luconazole. Several topical antifungal agents are effective therapy for VVC, and no agent is clearly 
superior (1, 35) and oral and topical antimycotics achieve entirely equivalent results (3, 25, 27, 
43, 44). For recurring Candida VVC, 10–14 days of induction therapy with a topical or oral azole, 
followed by luconazole at a dosage of 150 mg once per week for 6 months, is recommended (40). 
Complicated VVC requires topical therapy administered intravaginally daily for around 7 days or 
multiple doses of luconazole (150 mg every 72 h for 3 doses) (35). Therapy with azoles is less ef-
fective in treating non–C. albicans VVC (1). Candidiasis due to C. glabrata is frequently resistant to 
azole (including voriconazol). Topical boric acid at a dosage of 600 mg daily for 14 days (in gelatin 
capsule), may be successful (39). Other alternative treatments include topical 17% lucytosine cream 
alone or in combination with 3% AmB cream administered daily for 14 days; these agents must be 
compounded by a pharmacy. Results of many studies indicate that there is no need to implement 
treatment in sexual partners of patients suffering from VVC / rVVC (5). The Polish Gynecological 
Society recommends gathering an interview for the appearance of symptoms of a yeast infection in 
a sexual partner and, if conirmed, treatment by topical preparations (43).
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Cutaneous candidiasis
Candida spp. dermatitis can occur under several clinical forms. The most common form of 
yeast dermatitis is Candidal intertrigo (candidosis in tertriginosa, intertrigo candidamycetica), which 
locates in the skin folds, especially in case of obese people. In these places acute or subacute inlam-
mation is observed with an exudation. Epidermis shows signiicant maceration, cracks are pres-
ent. Around the main changes there are satellite eruptions with vesicles and pustules (16). Erosio 
interdigitalis blastomycetica (in tertrigo erosiva interdigitalis candidamycetica) is associated with 
people working in wet conditions. The most frequent location of the disease is the interdigital space, 
between the third and fourth inger of the hand. In the depths of this fold, inlammation develops 
with painful cracks. The infection may spread to adjacent interdigital spaces. A characteristic feature 
is the maceration of the epidermis, which exfoliates with collar around the circumference of candida 
inlamatory focus (16). Candidal folliculitis (folliculitis candida – cetica) is more common in people 
with reduced immunity, within the beard there are nasal pustular eruptions, from which Candida 
albicans are isolated. In the treatment of the cutaneus candidiasis, there are effective topical azoles 
and polyenes including clotrimazole, miconazole and nystatin. The infected area must be dry. The 
basic meaning in the treatment of candidiasis of the nail shaft has drainage. Paronychia is a Candida 
infection of the hand or foot where the nail and skin meet at the side or the base of a nail. Inlam-
mation manifested by edema, pain and purulent secretion. Skin typically presents as red, itchy, and 
hot, along with intense pain. Pus is usually present, along with gradual thickening and browning 
discoloration of the nail plate. The process is usually chronic and shows a period of remission and 
exacerbation. Nail plates undergo partial destruction, are grayed out, gray-brown, lose gloss, stratify 
and separate from the nail bed (3). In the nail infections caused by Candida spp. local treatment is 
usually ineffective. In typical cases, more effective oral terbinaine or itraconazole is used instead of 
oral griseofulvin (19). Terbinaine has a short and variable activity, which is conirmed by clinical 
trials. On the other hand, itraconazole seems to be effective at a dose of 200 mg 2 times a day for 7 
days a month for 3–4 months (6, 37).
CONCLUSION
The epidemiology of Candida spp. infections has changed in recent years. 
Candida albicans is the most common etiological factor responsible for oral, 
esophagus and skin candidiasis. In invasive infections and vaginal candidiasis 
(26, 43), other species of the Candida play an important role. Candida spp. sen-
sitivity to antifungal drugs can be predicted based on knowledge of the species. 
however, the sensitivity of individual isolates may be different than standards. 
In case of hIV positive patients with recurrent candidiasis of the oral cavity and 
esophagus, and in rare cases of adults with generalized candidiasis, isolates of 
C. albicans resistant to azoles are isolated. Pfaller and colleagues (33) reported 
susceptibility data for luconazole and voriconazole:
•  90.2% of the Candida spp. isolates were found to be susceptible to lu-
conazole; however, reduced luconazole susceptibility (deined as <75.0% 
susceptible) was observed in 13 of 31 species;
•  resistance to luconazole was shown to increase throughout time for 
C. parapsilosis, C. guilliermondii, C. lusitaniae, C. sake, and C. pelliculosa;
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•  luconazole resistance was found to be emerging in isolates of C. guillier-
mondii, C. inconspicua, C. rugosa, and C. norvegensis;
•  resistance to voriconazole was generally uncommon during the study; 
•  one-third of fluconazole-resistant isolates of C. albicans, C. glabra-
ta, C. tropicalis, C. rugosa, C. lipolytica, C. pelliculosa, C. apicola, 
C. haemulonii, C. humicola, C. lambica, and C. ciferrii remained suscep-
tible to voriconazole (32).
Resistance to the echinocandins is generally uncommon, with incidence rates 
ranging from 0%–1.7%. In total, 38% of echinocandin-resistant C. glabrata iso-
lates is also found to be resistant to luconazole (33). Resistance to both azoles and 
echinocandins is an important concern.
The majority of Candida spp. isolates are still sensitive to amphotericin B. 
Resistance to amphotericin B is very rare among C. albicans, C. tropicalis, and 
C. parapsilosis isolates. C. lusitaniae strains very often show clinically signiicant 
resistance to amphotericin B, but the frequency of this phenomenon has not been 
precisely determined (11). Some reports indicate that it is necessary to use this an-
tibiotic at maximum doses in infections caused by C. glabrata and C. krusei (46). 
The intrinsic resistance to antifungal therapy observed in some species, along with 
the development of acquired resistance during treatment in others, is becoming 
a major problem in the management of Candida spp. infections.
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